ScreenerHero

SVRA Savara Inc.

NAS · US · Healthcare · Biotechnology · savarapharma.com
4.880USD+4.95%Mkt Cap: 1.00B $P/E: —

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulati…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.00B USD
Enterprise Value1.04B USD
Revenue (TTM)—
Gross Profit-86.84M USD
Net Income (TTM)-118.84M USD
Revenue/Share—
Last Price4.880 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.90
PEG—
EV/EBITDA-7.27
EV/Revenue—
P/S—
P/B8.23
EPS (TTM)-0.58
EPS (Forward)-0.31
52W Range
3.34042% of range7.005
52W High7.005 USD
52W Low3.340 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.50%
ROA-46.89%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-101.04M USD
CapEx (TTM)22.00K USD
FCF Margin—
FCF Yield-5.72%
Net Debt-144.41M USD
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity0.15
Current Ratio10.13
Quick Ratio9.99
Book Value/Sh0.56 USD
Cash/Share0.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateApr 28, 2017
Analyst Consensus
Rating—
Target (Mean)10.94 USD
Upside (mean)+124.1%
Target Range9.000 USD – 16.00 USD
9.000+124.1% to mean16.00
# Analysts8
Ownership
Shares Out.204.93M
Float129.75M
Insiders2.55%
Institutions106.75%
Short Interest
Short Ratio29.3d
Short % Float24.66%
Short % Out.21.10%
Shares Short43.34M
Short (prev mo.)38.51M
Technical
SMA 505.365 (-9.0%)
SMA 2005.515 (-11.5%)
Beta0.20
S&P 52W Chg16.45%
Avg Vol (30d)1.96M
Avg Vol (10d)3.02M
Technical Indicators
RSI (14)40.8
MACD-0.1697
MACD Signal-0.1370
MACD Hist.-0.0326
BB Upper5.614 USD
BB Middle5.138 USD
BB Lower4.661 USD
BB Width18.56%
ATR (14)0.2560 USD
Vol Ratio (20d)1.09x